Obinutuzumab for the First-Line Treatment of Follicular Lymphoma – PubMed

In the Gallium trial looking at the role of Obinutuzumab vs rituximab in the first line treatment of FL, there was a 6% PFS benefit but no improvement in CR rates.

Read the full article here

Related Articles